Molecule
Potassium acetate is an osmotic laxative indicated as a source of potassium, for the addition to large volume intravenous fluids, to prevent or correct hypokalemia in patients with restricted or no oral intake. MedsAcross supplies Potassium acetate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Potassium Acetate Injection, USP, 40 mEq is indicated as a source of potassium, for the addition to large volume intravenous fluids, to prevent or correct hypokalemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.
Source: US FDA prescribing information
Potassium Acetate Injection, USP, 40 mEq is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. ECG and serum potassium should be monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of milliequivalents (mEq) of potassium (K + ) with an equal number of milliequivalents of acetate (CH 3 COO – ). Maximum infusion rate: The infusion rate should not exceed 1 mEq/kg/hr. Normal daily requirements: Newborn: 2–6 mEq/kg/24 hr. Children: 2–3 mEq/kg/24 hr. Adult: 40–80 mEq/24 hr. Intraosseous infusion can be an alternate route for drug administration when intravenous access is not readily available.
Source: US FDA prescribing information
Potassium administration is contraindicated in patients with severe renal insufficiency or adrenal insufficiency and in diseases where high potassium levels may be encountered.
Source: US FDA prescribing information
Potassium Acetate Injection, USP, 40 mEq must be diluted before use. To avoid potassium intoxication, infuse potassium-containing solutions slowly. Potassium replacement therapy should be monitored whenever possible by continuous or serial electrocardiography (ECG). Serum potassium levels are not necessarily dependable indicators of tissue potassium levels. Solutions which contain potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present. In patients with diminished renal function, administration of solutions containing potassium ions may result in potassium retention. Solutions containing acetate ions should be used with great care in patients with metabolic or respiratory alkalosis.
Source: US FDA prescribing information
Adverse reactions involve the possibility of potassium intoxication. The signs and symptoms of potassium intoxication include paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities such as disappearance of P waves, spreading and slurring of the QRS complex with development of a biphasic curve and cardiac arrest.
Source: US FDA prescribing information
Store at 20 to 25ºC (68 to 77ºF).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Potassium acetate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Potassium acetate 3.93 g/20 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Potassium acetate 9815 mg/50 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Potassium acetate 200 mEq/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Potassium acetate 9800 mg/50 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 20 July 1984 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Potassium acetate in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 4 presentations of Potassium acetate and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Potassium acetate on 20 July 1984, according to Drugs@FDA.
No listed presentation of Potassium acetate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Potassium acetate is classified under ATC code B05XA17 (Potassium acetate).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.